Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MIF | P14174 | 13/20 | 0.53 |
| ▸ | TRPA1 | O75762 | 3/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.49 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.49 |
| ▸ | HPGD | P15428 | 1/20 | 0.49 |
| ▸ | CYP2E1 | P05181 | 1/20 | 0.35 |
| ▸ | CYP2A6 | P11509 | 1/20 | 0.35 |
| ▸ | HIF1A | Q16665 | 1/20 | 0.35 |
| ▸ | CYP2A13 | Q16696 | 1/20 | 0.35 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.35 |
| ▸ | NAAA | Q02083 | 4/20 | 0.35 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL483536 | 0.77 | MIF (0.74) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL189832 | 0.73 | TRPA1 (0.38) | TRPA1ALDH1A1 | |
| SCHEMBL50479 | 0.73 | TSHR (0.38) | — | |
| SCHEMBL4178543 | 0.72 | MIF (0.44) | MIFALDH1A1CYP3A4HPGDHIF1A | |
| SCHEMBL2107951 | 0.71 | MIF (0.65) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL2655669 | 0.70 | TDP1 (0.42) | — | |
| SCHEMBL25333223 | 0.69 | MIF (0.69) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL1551628 | 0.69 | MIF (1.00) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL2341886 | 0.69 | MIF (0.62) | MIFTRPA1ALDH1A1CYP3A4HPGD | |
| SCHEMBL10651510 | 0.69 | MIF (0.62) | MIFTRPA1ALDH1A1CYP3A4HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8642647-B2 | N1-benzo[1,3]dioxol-5-ylmethyl-N2-substituted biguanide derivative, preparation method thereof, and pharmaceutical composition containing same | HANALL BIOPHARMA CO., LTD. (KR) | 2014-02-04 | — | — | US | disclosed |
| US-20110207810-A1 | N1-BENZO[1,3]DIOXOL-5-YLMETHYL-N2-SUBSTITUTED BIGUANIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | HANALL BIOPHARMA CO., LTD. (KR) | 2011-08-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110207810-A1 | N1-BENZO[1,3]DIOXOL-5-YLMETHYL-N2-SUBSTITUTED BIGUANIDE DERIVATIVE, PREPARATION METHOD THEREOF, AND PHARMACEUTICAL COMPOSITION CONTAINING SAME | BRCA1, TP53, SLC5A1 | MIF 3559/4885TRPA1 1359/4885ALDH1A1 1560/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.